Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, April 2009, p. 1698-1700, Vol. 53, No. 4
0066-4804/09/$08.00+0 doi:10.1128/AAC.01549-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Infectious Disease Research,1 Chemical Sciences, Wyeth Research, Pearl River, New York2
Received 20 November 2008/ Returned for modification 22 December 2008/ Accepted 22 January 2009
The in vivo efficacy of piperacillin in combination with the penem inhibitor BLI-489 was determined using acute lethal systemic infections in mice. On the basis of preliminary results with various ratios, a dosing ratio of 8:1 was found to be optimal for retention of enhanced efficacy. Piperacillin-BLI-489 dosed at an 8:1 ratio was efficacious against murine infections caused by class A (including extended-spectrum β-lactamases), class C (AmpC), and class D β-lactamase-expressing pathogens.
Published ahead of print on 2 February 2009.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»